BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1115 related articles for article (PubMed ID: 12564040)

  • 1. [Immunotherapy: new insights].
    Geissler M; Weth R
    Praxis (Bern 1994); 2002 Dec; 91(51-52):2236-46. PubMed ID: 12564040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunobiology and gene-based immunotherapy of hepatocellular carcinoma.
    Geissler M; Mohr L; Ali MY; Grimm CF; Ritter M; Blum HE
    Z Gastroenterol; 2003 Nov; 41(11):1101-10. PubMed ID: 14648380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Dendritic cells: orchestration of the immune response].
    Martinon-Ego C; Berthier R
    Ann Biol Clin (Paris); 2000; 58(5):541-56. PubMed ID: 11022098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune based therapies in cancer.
    Krüger C; Greten TF; Korangy F
    Histol Histopathol; 2007 Jun; 22(6):687-96. PubMed ID: 17357098
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T-cell epitope peptide vaccines.
    Elsawa SF; Rodeberg DA; Celis E
    Expert Rev Vaccines; 2004 Oct; 3(5):563-75. PubMed ID: 15485336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antitumor immunity and cellular cancer therapies].
    Catros-Quemener V; Bouet F; Genetet N
    Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current state and perspectives of dendritic cell vaccination in cancer immunotherapy.
    Farkas A; Conrad C; Tonel G; Borbenyi Z; Kemeny L; Dobozy A; Nestle FO
    Skin Pharmacol Physiol; 2006; 19(3):124-31. PubMed ID: 16612139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
    Engelhard VH; Bullock TN; Colella TA; Mullins DW
    Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: to use or not to use?
    Strioga MM; Darinskas A; Pasukoniene V; Mlynska A; Ostapenko V; Schijns V
    Vaccine; 2014 Jul; 32(32):4015-24. PubMed ID: 24837511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dendritic cell preparation for immunotherapeutic interventions.
    Simon T; Fonteneau JF; Grégoire M
    Immunotherapy; 2009 Mar; 1(2):289-302. PubMed ID: 20635946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current developments in cancer vaccines and cellular immunotherapy.
    Ribas A; Butterfield LH; Glaspy JA; Economou JS
    J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer vaccines. Any future?
    Myc LA; Gamian A; Myc A
    Arch Immunol Ther Exp (Warsz); 2011 Aug; 59(4):249-59. PubMed ID: 21644030
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy.
    Schultze JL; Grabbe S; von Bergwelt-Baildon MS
    Trends Immunol; 2004 Dec; 25(12):659-64. PubMed ID: 15530836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerations on clinical use of T cell immunotherapy for cancer.
    Plautz GE; Cohen PA; Shu S
    Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active specific T-cell-based immunotherapy for cancer: nucleic acids, peptides, whole native proteins, recombinant viruses, with dendritic cell adjuvants or whole tumor cell-based vaccines. Principles and future prospects.
    Fernandez N; Duffour MT; Perricaudet M; Lotze MT; Tursz T; Zitvogel L
    Cytokines Cell Mol Ther; 1998 Mar; 4(1):53-65. PubMed ID: 9557217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The repertoire of human tumor-associated epitopes--identification and selection of antigens and their application in clinical trials.
    Haen SP; Rammensee HG
    Curr Opin Immunol; 2013 Apr; 25(2):277-83. PubMed ID: 23619309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [mRNA-transfected dendritic cells: a promising strategy in immunotherapy].
    Maisnier-Patin K; Crabé S; Breton G; Dupuy FP; Yassine-Diab B; Sékaly RP
    Med Sci (Paris); 2007 Mar; 23(3):279-84. PubMed ID: 17349289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.